Results 21 to 30 of about 35,888 (296)

Receipt and duration of buprenorphine treatment during pregnancy and postpartum periods in a national privately-insured cohort

Drug and Alcohol Dependence Reports, 2023
Background: Research gaps exist on the use of medications for opioid use disorder (OUD) among birthing people. Methods: This retrospective cohort study included people who underwent childbirth deliveries during 2017-2020 and had a diagnosis of OUD ...
Xi Wang, Zachary Meisel, Katherine Kellom, Jennifer Whitaker, Douglas Strane, Anyun Chatterjee, Rebecka Rosenquist, Meredith Matone   +7 more
doaj   +1 more source

Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study

Addiction Science & Clinical Practice, 2022
Background Residential treatment is a common approach for treating opioid use disorder (OUD), however, few studies have directly compared it to outpatient treatment.
Daniel M. Hartung, Sheila Markwardt, Kirbee Johnston, Jonah Geddes, Robin Baker, Gillian Leichtling, Christi Hildebran, Brian Chan, Ryan R. Cook, Dennis McCarty, Udi Ghitza, P. Todd Korthuis   +11 more
doaj   +1 more source

Attending a Biopsychosocially Focused Buprenorphine Training Improves Clinician Attitudes

Frontiers in Psychiatry, 2021
Objective: Substance use disorders remain highly stigmatized. Access to medications for opioid use disorder is poor. There are many barriers to expanding access including stigma and lack of medical education about substance use disorders. We enriched the
Holly Ann Russell, Brian Smith, Mechelle Sanders, Elizabeth Loomis   +3 more
doaj   +1 more source

The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State

Addiction Science & Clinical Practice, 2022
Background Opioid use disorder (OUD) is a serious health condition that is effectively treated with buprenorphine. However, only a minority of people with OUD are able to access buprenorphine.
Caleb J. Banta-Green, Mandy D. Owens, Jason R. Williams, Jeanne M. Sears, Anthony S. Floyd, Wendy Williams-Gilbert, Susan Kingston   +6 more
doaj   +1 more source

A conceptual framework for how structural changes in emerging acute substance use service models can reduce stigma of medications for opioid use disorder

Frontiers in Psychiatry, 2023
Stigma toward people taking medication for opioid use disorder (MOUD) is prevalent, harmful to the health and well-being of this population, and impedes MOUD treatment resource provision, help-seeking, and engagement in care.
Timothy D. Becker, Timothy D. Becker, Evan L. Eschliman, Ashish P. Thakrar, Lawrence H. Yang, Lawrence H. Yang   +5 more
doaj   +1 more source

Methamphetamine use and utilization of medications for opioid use disorder among rural people who use drugs [PDF]

, 2023
BACKGROUND: Methamphetamine use is common among persons with opioid use disorder. This study evaluated associations between methamphetamine use and treatment with agonist medications for opioid use disorder (MOUD, specifically buprenorphine, and/or ...
Stopka, Thomas J., Jenkins, Wiley D., Friedmann, Peter D., Chan, Brian, Brown, Randall, Seal, David W., Young, April M., Tsui, Judith I., Feinberg, Judith, Smith, Gordon S., Consortium, On Behalf of the Rural Opioid Initiative, Fredericksen, Rob, Mixson, L. Sarah, Whitney, Bridget M., de Gijsel, David, Delaney, Joseph A., Pho, Mai T., Go, Vivian F., Cooper, Hannah L.F., Crane, Heidi M., Miller, William C., Westergaard, Ryan, Korthuis, P. Todd, Zule, William A.   +23 more
core   +4 more sources

Discordance in Addressing Opioid Crisis in Rural Communities: Patient and Provider Perspectives

Pharmacy, 2022
Providing patient-centered care to manage chronic pain and opioid use disorder (OUD) is associated with improved health outcomes. However, adopting a holistic approach to providing care is often challenging in rural communities.
Bonyan Qudah, Martha A. Maurer, David A. Mott, Michelle A. Chui   +3 more
doaj   +1 more source

Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA)

Annals of Medicine, 2023
Introduction Treatment for opioid use disorder (OUD) with diacetylmorphine is an evidence-based form of drug treatment, but it is not available in the United States (US).
Sean T. Allen, Kristin E. Schneider, Saba Rouhani, Rebecca Hamilton White, Miles Morris, Jill Owczarzak, Susan G. Sherman   +6 more
doaj   +1 more source

Six-month outcomes of the HOPE smartphone application designed to support treatment with medications for opioid use disorder and piloted during an early statewide COVID-19 lockdown

Addiction Science & Clinical Practice, 2022
Background Morbidity and mortality related to opioid use disorder (OUD) in the U.S. is at an all-time high. Innovative approaches are needed to address gaps in retention in treatment with medications for opioid use disorder (MOUD). Mobile health (mHealth)
Jacqueline Hodges, Marika Waselewski, William Harrington, Taylor Franklin, Kelly Schorling, Jacqueline Huynh, Alexa Tabackman, Kori Otero, Karen Ingersoll, Nassima Ait-Daoud Tiouririne, Tabor Flickinger, Rebecca Dillingham   +11 more
doaj   +1 more source

Medication-Assisted Treatment for Opioid-Use Disorder [PDF]

Mayo Clinic Proceedings, 2019
The United States is in the midst of a national opioid epidemic. Physicians are encouraged both to prevent and treat opioid-use disorders (OUDs). Although there are 3 Food and Drug Administration-approved medications to treat OUD (methadone, buprenorphine, and naltrexone) and there is ample evidence of their efficacy, they are not used as often as they
Tyler S. Oesterle, Nuria J. Thusius, Teresa A. Rummans, Mark S. Gold   +3 more
openaire   +2 more sources